Chitin-glucan improves important pathophysiological features of irritable bowel syndrome
World J Gastroenterol. 2024 Apr 28;30(16):2258-2271. doi: 10.3748/wjg.v30.i16.2258. ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) is one of the most frequent and debilitating conditions leading to...
Patients’ knowledge about the uses, risks, and beliefs surrounding the regulation and safety of Cannabis sativa L. in Peru
Heliyon. 2024 Mar 21;10(7):e27068. doi: 10.1016/j.heliyon.2024.e27068. eCollection 2024 Apr 15. ABSTRACT In recent decades, there has been a significant rise in the utilization of medical...
Cannabinoid hyperemesis syndrome
BMJ Case Rep. 2024 Apr 30;17(4):e256921. doi: 10.1136/bcr-2023-256921. ABSTRACT SummaryCannabis use is legalised in many countries. We present a patient in their 40s who complained...
Drug use and COVID-19 testing, vaccination, and infection among underserved, minority communities in Miami, Florida
PLoS One. 2024 Apr 30;19(4):e0297327. doi: 10.1371/journal.pone.0297327. eCollection 2024. ABSTRACT The Coronavirus Disease 2019 (COVID-19) pandemic has disproportionately impacted people who use drugs (PWUD). This...
Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America’s Poison Centers
Clin Toxicol (Phila). 2024 Apr 30:1-11. doi: 10.1080/15563650.2024.2340115. Online ahead of print. ABSTRACT INTRODUCTION: Since the passage of the Farm Bill in 2018, the availability...
Cannabis Legalization and Resource Use for Ingestions by Young Children
Pediatrics. 2024 May 1:e2024065881. doi: 10.1542/peds.2024-065881. Online ahead of print. ABSTRACT OBJECTIVE: In conjunction with widening legalization, there has been a rapid rise in unintentional...
Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses (Equus caballus)
Front Vet Sci. 2024 Apr 12;11:1356463. doi: 10.3389/fvets.2024.1356463. eCollection 2024. ABSTRACT The pharmacokinetics and tolerability of cannabinoids and their metabolites were determined in eight horses...
The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect
Pharmacol Biochem Behav. 2024 Apr 26:173776. doi: 10.1016/j.pbb.2024.173776. Online ahead of print. ABSTRACT Alcohol use disorder (AUD) affects >15 million people in the United States....
Neuromelanin levels in individuals with substance use disorders: A systematic review and meta-analysis
Neurosci Biobehav Rev. 2024 Apr 27;161:105690. doi: 10.1016/j.neubiorev.2024.105690. Online ahead of print. ABSTRACT Dopamine’s role in addiction has been extensively studied, revealing disruptions in its...
Discovery and development of macrocyclic peptide modulators of the cannabinoid 2 receptor
J Biol Chem. 2024 Apr 26:107330. doi: 10.1016/j.jbc.2024.107330. Online ahead of print. ABSTRACT The cannabinoid-type 2 receptor (CB2R), a G protein-coupled receptor (GPCR), is an...
Discovery and development of macrocyclic peptide modulators of the cannabinoid 2 receptor
J Biol Chem. 2024 Apr 26:107330. doi: 10.1016/j.jbc.2024.107330. Online ahead of print. ABSTRACT The cannabinoid-type 2 receptor (CB2R), a G protein-coupled receptor (GPCR), is an...
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder
Pain Ther. 2024 Apr 27. doi: 10.1007/s40122-024-00599-1. Online ahead of print. ABSTRACT This narrative review explores current insights into the potential use of medicinal cannabis-related...
Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice
Psychopharmacology (Berl). 2024 Apr 27. doi: 10.1007/s00213-024-06591-z. Online ahead of print. ABSTRACT RATIONALE/OBJECTIVES: Targeting cannabinoid receptor type 1 (CB1R) has shown promise for treating opioid...
Phytocannabinoids in neuromodulation: from omics to epigenetics
J Ethnopharmacol. 2024 Apr 25:118201. doi: 10.1016/j.jep.2024.118201. Online ahead of print. ABSTRACT BACKGROUND: Recent developments in metabolomics, transcriptomic and epigenetics open up new horizons regarding...
Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials
Epilepsy Behav. 2024 Apr 26;156:109805. doi: 10.1016/j.yebeh.2024.109805. Online ahead of print. ABSTRACT OBJECTIVE: Dravet syndrome is a rare, early childhood-onset epileptic and developmental encephalopathy. Responses...